Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Monoclonal Antibodies (mAbs) Market 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Infectious Diseases, Hematological Disease, Other Applications), By End-Users (Hospitals, Specialty Centers, Other End-Users), And By Region, Opportunities And Strategies – Global Forecast To 2033

Starting Price : $5000.00 | Pages : 279 | Published : April 2024 | | Format : pdf

Purchase Options
Request Sample
Request For Discount

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Monoclonal Antibodies (mAbs)Market Definition

Monoclonal antibodies (mAbs) are laboratory-produced antibodies that specifically bind to target molecules with high affinity, avidity and specificity. This binding results in inhibition of the target molecule’s biological function by blocking its interaction with other receptor proteins or directing its destruction and elimination.

The monoclonal antibodies (mAbs) market consists of sales by entities (organizations, sole traders and partnerships), that produce monoclonal antibodies used to treat various medical conditions including cancer, inflammatory and autoimmune diseases.

Monoclonal Antibodies (mAbs)Market Size

The global monoclonal antibodies (mAbs) market reached a value of nearly $209,853.6 million in 2023, having grown at a compound annual growth rate (CAGR) of 12.8% since 2018. The market is expected to grow from $209,853.6 million in 2023 to $ 375,412.3 million in 2028 at a rate of 12.3%. The market is then expected to grow at a CAGR of 12.4% from 2028 and reach $673,130.7 million in 2033.  

Growth in the historic period resulted from the strong economic growth in emerging markets, increasing focus on personalized medicine, increase in R&D expenditure and government initiatives. Factors that negatively affected growth in the historic period were pricing pressures from regulators.

Going forward, increasing chronic diseases, rise in healthcare expenditure, increasing prevalence of cancer and increasing aging population will drive the growth. Factor that could hinder the growth of the monoclonal antibodies (mAbs) market in the future include high cost in development of monoclonal antibodies, stringent regulatory guidelines and usage of surrogate endpoints in clinical trials.

Monoclonal Antibodies (mAbs) Market Drivers

The key drivers of the monoclonal antibodies (mabs) market include:

Increasing Chronic Diseases

The increasing number of chronic diseases is expected to contribute to the growth of the monoclonal antibodies MAbs market going forward. Chronic diseases often require long-term medication management and patients with these conditions can benefit greatly from personalized treatment approaches. Monoclonal antibodies provide a customized way to target and fight against specific elements of disease pathology. According to the Centres for Disease Control and Prevention, a US-based national public health agency, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA.   According to the National Library of Medicine, a US-based agency, the number of individuals in the US aged 50 and older who have at least one chronic condition will increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. The increasing number of chronic diseases is expected to generate high demand for the mAbs market.

Monoclonal Antibodies (mAbs) Market Restraints

The key restraints on the monoclonal antibodies (mabs) market include:

Stringent Regulatory Guidelines

Stringent regulations related to safety, efficacy and quality are projected to act as a major challenge for players operating in the monoclonal antibodies market. All medicines and treatments go through stringent testing in the lab (pre-clinical research) and in small groups of patients (clinical research). The European Medicines Agency (EMA) and The United States Food and Drug Administration (FDA) are the two main bodies regulating these novel therapies while getting them to market. Health Canada uses mAb specific guidelines from EMA or USFDA when necessary. The SAHPRA (South African Health Products Authority) biosimilar guideline has an annex on mAbs which focuses on non-clinical and clinical aspects. The Russian Federation has issued general product registration guideline/s with very brief information about mAbs. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market.

Monoclonal Antibodies (mAbs) Market Trends

Major trends shaping the monoclonal antibodies (mabs) market include:

Investment in Targeted and Combination Therapy

Companies in the monoclonal antibodies (mAbs) market are investing in targeted and combination therapy, which has been proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease.    For instance, in September 2022, the European Union (EU) granted approval for AstraZeneca's Evusheld (comprising tixagevimab and cilgavimab, previously known as AZD7442). This long-acting antibody combination was authorized for treating COVID-19 in adults and adolescents (aged 12 years and older, weighing at least 40 kg) who do not need supplemental oxygen and face an elevated risk of developing severe COVID-19.   Also, in January 2020, European Commission has granted conditional marketing authorization for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.

Integration of Artificial Intelligence for Accelerated Innovation

Companies in the monoclonal antibodies (mAbs) market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI solutions can successfully identify disease patterns in large datasets and this information can be used to determine the optimal drug formulations for treating various diseases. For instance, in October 2023, BigHat Biosciences a US- based a protein therapeutics company is leveraging artificial intelligence (AI) and machine learning (ML) to drive innovation in the development of monoclonal antibodies (mAbs). The company has built a platform that integrates the best of AI/ML and life sciences wet lab to accelerate the development of antibody fragments. By aligning to areas with high-quality assays predictive of clinical efficacy and safety, Biosciences aims to optimize its molecules to those measurements, enabling the rapid iteration of its AI/ML methods. The company's focus is on areas with well-understood biology, especially high-resolution and high-quality assays and it is exploring new, green fields of molecular space made possible by its AI/ML integrated platform.

Opportunities And Recommendations In The Monoclonal Antibodies (mAbs) Market

Opportunities – The top opportunities in the monoclonal antibodies (mAbs) market segmented by source will arise in the human segment, which will gain $80,220.5 million of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by application will arise in the anti-cancer segment, which will gain $65,857.2 million of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by end-users will arise in the hospitals segment, which will gain $108,459.7 million of global annual sales by 2028. The monoclonal antibodies (mAbs) market size will gain the most in USA at $67,883.9 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the monoclonal antibodies (mAbs) companies to focus on advancing targeted and combination therapies for market growth, focus on driving market growth through product innovation, focus on cancer biologics R&D, focus on revolutionizing research with AI integration, focus on human and humanized segments for growth, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, focus on diversifying distribution channels, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on strategic promotion, focus on immunological and anti-cancer segments and focus on specialty centers and hospitals for strategic growth.

Monoclonal Antibodies (mAbs) Market Segmentation

The monoclonal antibodies (mabs) market is segmented by source, by application and by end-users.

By Source –
The monoclonal antibodies (mabs) market is segmented by source into:
    • a) Murine
    • b) Chimeric
    • c) Humanized
    • d) Human
The human market was the largest segment of the monoclonal antibodies (mAbs) market segmented by source, accounting for 43.2% or $90,590.6 million of the total in 2023. Going forward, the humanized segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by source, at a CAGR of 14.2% during 2023-2028.

By Application –
The monoclonal antibodies (mabs) market is segmented by application into:
    • a) Anti-Cancer
    • b) Immunological
    • c) Infectious Diseases
    • d) Hematological Disease
    • d) Other Applications
The anti-cancer market was the largest segment of the monoclonal antibodies (mAbs) market segmented by application, accounting for 38.9% or $81,664.8 million of the total in 2023. Going forward, the immunological segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by application, at a CAGR of 13.4% during 2023-2028.

By End Users –
The monoclonal antibodies (mabs) market is segmented by end users into:
    • a) Hospitals
    • b) Specialty Centers
    • c) Other End-Users
The hospitals market was the largest segment of the relays market segmented by end-users, accounting for 65.4% or $137,333.3 million of the total in 2023. Going forward, the specialty centers segment is expected to be the fastest growing segment in the relays market segmented by end-users, at a CAGR of 13.0% during 2023-2028.

By Geography - The monoclonal antibodies (mabs) market is segmented by geography into:
      o Asia Pacific
      • • China
      • • India
      • • Japan
      • • Australia
      • • Indonesia
      • • South Korea
      o North America
      • • USA
      o South America
      • • Brazil
      o Western Europe
      • • France
      • • Germany
      • • UK
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
North America was the largest region in the monoclonal antibodies (mAbs) market, accounting for 45.8% or $96,118.7 million of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the monoclonal antibodies (mAbs) market will be Asia Pacific and Western Europe where growth will be at CAGRs of 13.6% and 12.9% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 12.5% and 9.20% respectively.

Monoclonal Antibodies (Mabs) Market Competitive Landscape

Major Competitors are:

  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • F. Hoffman-La Roche Ltd.
  • Bristol Myers Squibb
  • GlaxoSmithKline plc

    • Other Competitors Include:

  • Eli Lilly And Company
  • Pfizer Inc
  • Amgen Inc
  • Novartis AG
  • Eisai Co., Ltd
  • Biocon Limited
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries Ltd
  • BeiGene, Ltd.
  • Shanghai Junshi Biosciences Co., Ltd
  • Innovent Biologics, Inc
  • Chugai Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Mitsubishi Tanabe Pharma Corporation
  • Celltrion, Inc.
  • Samsung Biologics Co., Ltd.
  • LG Chem Life Sciences
  • CSL Limited
  • Cochlear Limited
  • ResMed Inc.
  • Sino Biological
  • WuXi Biologics
  • 3SBio Inc.
  • Shanghai Henlius Biotech, Inc.
  • CStone Pharmaceuticals
  • Sanofi S.A.
  • AstraZeneca
  • Merck KGaA
  • Bayer AG
  • EPIVAX, Inc.
  • Genentech
  • Boehringer Ingelheim Grifols
  • Almirall
  • BioInvent
  • Alligator Bioscience
  • Dompe Farmaceutici
  • BIOCAD
  • Sistema-Biotech
  • Nanolek
  • Mabion
  • Polpharma Biologics
  • Bioceros
  • Eurofarma
  • Hypermarcas
  • Biolab Farmacêutica
  • Laboratorios Richmond
  • andes Biotechnologies
  • Tecnoquimicas
  • Labinca
  • Libbs Farmaceutica
  • Hikma Pharmaceuticals
  • Neopharm
  • BBI Solutions
  • APC Pharma
  • EPICIO
  • Medical Union Pharmaceuticals
  • South Egypt Drug Industries Co. Pharmaceutical
  • Vacsera Pharma
  • Aspen Pharmacare
  • Amoun Pharmaceuticals CO Ltd.
  • 54gene
  • Baxter International
  • Altis Biologics
  • Cipla Medpro South Africa
  • EPIVAX, Inc.
  • Genentech

      • Table Of Contents

      1 Executive Summary

      1.1 Monoclonal Antibodies (mAbs) – Market Attractiveness And Macro economic Landscape

      2 Table Of Contents

      3 List Of Tables

      4 List Of Figures

      5 Report Structure

      6 Market Characteristics

      6.1 General Market Definition

      6.2 Summary

      6.3 Monoclonal Antibodies (mAbs) Market Definition And Segmentations

      6.4 Market Segmentation By Source

      6.4.1 Murine

      6.4.2 Chimeric

      6.4.3 Humanized

      6.4.4 Human

      6.5 Market Segmentation By Application

      6.5.1 Anti-Cancer

      6.5.2 Immunological

      6.5.3 Infectious Disease

      6.5.4 Hematological Disease

      6.5.5 Other Applications

      6.6 Market Segmentation By End-Users

      6.6.1 Hospitals

      6.6.2 Specialty Centers

      6.6.3 Other End-Users

      7 Major Market Trends

      7.1 Investment in Targeted and Combination Therapy

      7.2 Strategic Partnerships And Collaborations Among Market Players To Drive Innovation and Expansion In The Market

      7.3 R&D Investments Revolutionizing Treatment

      7.4 Integration of Artificial Intelligence for Accelerated Innovation

      7.5 Product Innovation In Novel Therapies and Biosimilars Expands Treatment Options

      8 Monoclonal Antibodies (mAbs) Market – Macro-Economic Scenario

      8.1 COVID-19 Impact On The Monoclonal Antibodies (mAbs) Market

      8.2 Impact Of The War In Ukraine On The Monoclonal Antibodies (mAbs) Market

      8.3 Impact Of High Inflation On The Monoclonal Antibodies (mAbs) Market

      9 Global Market Size and Growth

      9.1 Market Size

      9.2 Historic Market Growth, 2018 – 2023, Value ($ Million)

      9.2.1 Market Drivers 2018 – 2023

      9.2.2 Market Restraints 2018 – 2023

      9.3 Forecast Market Growth, 2023 – 2028, 2033F Value ($ Million)

      9.3.1 Market Drivers 2023 – 2028

      9.3.2 Market Restraints 2023 – 2028

      10 Global Monoclonal Antibodies (mAbs) Market Segmentation

      10.1 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      10.2 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      10.3 Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      11 Monoclonal Antibodies (mAbs) Market, Regional and Country Analysis

      11.1 Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      11.2 Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12 Asia-Pacific Market

      12.1 Summary

      12.1.1 Market Overview

      12.1.2 Region Information

      12.1.3 Market Information

      12.1.4 Background Information

      12.1.5 Government Initiatives

      12.1.6 Regulations

      12.1.7 Regulatory Bodies

      12.1.8 Major Associations

      12.1.9 Taxes Levied

      12.1.10 Corporate Tax Structure

      12.1.11 Investments

      12.1.12 Major Companies

      12.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market: Country Analysis

      12.6 China Market

      12.7 Summary

      12.7.1 Market Overview

      12.7.2 Country Information

      12.7.3 Market Information

      12.7.4 Background Information

      12.7.5 Government Initiatives

      12.7.6 Regulations

      12.7.7 Regulatory Bodies

      12.7.8 Major Associations

      12.7.9 Taxes Levied

      12.7.10 Corporate Tax Structure

      12.7.11 Investments

      12.7.12 Major Companies

      12.8 China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.9 China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.1 China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.11 India Market

      12.12 India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.13 India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.14 India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.15 Japan Market

      12.16 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.17 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.18 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.19 Australia Market

      12.2 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.21 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.22 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.23 Indonesia Market

      12.24 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.25 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.26 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.27 South Korea Market

      12.28 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.29 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      12.3 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13 Western Europe Market

      13.1 Summary

      13.1.1 Market Overview

      13.1.2 Region Information

      13.1.3 Market Information

      13.1.4 Background Information

      13.1.5 Government Initiatives

      13.1.6 Regulations

      13.1.7 Regulatory Bodies

      13.1.8 Major Associations

      13.1.9 Taxes Levied

      13.1.10 Corporate tax structure

      13.1.11 Investments

      13.1.12 Major Companies

      13.2 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.3 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.4 Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.5 Western Europe Monoclonal Antibodies (mAbs) Market: Country Analysis

      13.6 UK Market

      13.7 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.8 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.9 UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.1 Germany Market

      13.11 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.12 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.13 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.14 France Market

      13.15 France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.16 France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      13.17 France Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14 Eastern Europe Market

      14.1 Summary

      14.1.1 Market Overview

      14.1.2 Region Information

      14.1.3 Market Information

      14.1.4 Background Information

      14.1.5 Government Initiatives

      14.1.6 Regulations

      14.1.7 Regulatory Bodies

      14.1.8 Major Associations

      14.1.9 Taxes Levied

      14.1.10 Corporate Tax Structure

      14.1.11 Investments

      14.1.12 Major Companies

      14.2 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14.3 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14.4 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14.5 Eastern Europe Monoclonal Antibodies (mAbs) Market: Country Analysis

      14.6 Russia Market

      14.7 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14.8 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      14.9 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15 North America Market

      15.1 Summary

      15.1.1 Market Overview

      15.1.2 Region Information

      15.1.3 Market Information

      15.1.4 Background Information

      15.1.5 Government Initiatives

      15.1.6 Regulations

      15.1.7 Regulatory Bodies

      15.1.8 Major Associations

      15.1.9 Taxes Levied

      15.1.10 Corporate Tax Structure

      15.1.11 Investments

      15.1.12 Major Companies

      15.2 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15.3 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15.4 North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15.5 North America Monoclonal Antibodies (mAbs) Market: Country Analysis

      15.6 USA Market

      15.7 Summary

      15.7.1 Market Overview

      15.7.2 Country Information

      15.7.3 Market Information

      15.7.4 Background Information

      15.7.5 Government Initiatives

      15.7.6 Regulations

      15.7.7 Regulatory Bodies

      15.7.8 Major Associations

      15.7.9 Taxes Levied

      15.7.10 Corporate Tax Structure

      15.7.11 Investments

      15.7.12 Major Companies

      15.8 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15.9 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      15.1 USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16 South America Market

      16.1 Summary

      16.1.1 Market Overview

      16.1.2 Region Information

      16.1.3 Market Information

      16.1.4 Background Information

      16.1.5 Government Initiatives

      16.1.6 Regulations

      16.1.7 Regulatory Bodies

      16.1.8 Major Associations

      16.1.9 Taxes Levied

      16.1.10 Corporate Tax Structure

      16.1.11 Investments

      16.1.12 Major Companies

      16.2 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16.3 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16.4 South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16.5 South America Monoclonal Antibodies (mAbs) Market: Country Analysis

      16.6 Brazil Market

      16.7 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16.8 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      16.9 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      17 Middle East Market

      17.1 Summary

      17.1.1 Market Overview

      17.1.2 Region Information

      17.1.3 Market Information

      17.1.4 Background Information

      17.1.5 Government Initiatives

      17.1.6 Regulations

      17.1.7 Regulatory Bodies

      17.1.8 Major Associations

      17.1.9 Taxes Levied

      17.1.10 Corporate Tax Structure

      17.1.11 Investments

      17.1.12 Major Companies

      17.2 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      17.3 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      17.4 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      18 Africa Market

      18.1 Summary

      18.1.1 Market Overview

      18.1.2 Region Information

      18.1.3 Market Information

      18.1.4 Background Information

      18.1.5 Government Initiatives

      18.1.6 Regulations

      18.1.7 Regulatory Bodies

      18.1.8 Major Associations

      18.1.9 Taxes Levied

      18.1.10 Corporate Tax Structure

      18.1.11 Investment

      18.1.12 Major Companies

      18.2 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      18.3 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      18.4 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

      19 Competitive Landscape And Company Profiles

      19.1 Company Profiles

      19.2 Johnson & Johnson

      19.2.1 Company Overview

      19.2.2 Products And Services

      19.2.3 Business Strategy

      nal overview

      19.3 Merck & Co., Inc.

      19.3.1 Company Overview

      19.3.2 Products And Services

      19.3.3 Business Strategy

      19.3.4 Financial Overview

      19.4 F. Hoffman-La Roche Ltd.

      19.4.1 Company Overview

      19.4.2 Products And Services

      19.4.3 Business Strategy

      19.4.4 Financial Overview

      19.5 Bristol Myers Squibb

      19.5.1 Company Overview

      19.5.2 Products And Services

      19.5.3 Business Strategy

      19.5.4 Financial Overview

      19.6 GlaxoSmithKline plc

      19.6.1 Company Overview

      19.6.2 Products And Services

      19.6.3 Business Strategy

      19.6.4 Financial performance

      20 Key Mergers And Acquisitions

      20.1 Syngene Acquired Stelis Biopharma

      20.2 Merck Acquired Prometheus Biosciences

      20.3 Biocon Biologics Acquired Viatris Inc

      20.4 Incyte Acquired Villaris Therapeutics

      20.5 FUJIFILM Corporation Acquired Atara Biotherapeutics

      20.6 Exelixis Inc. Acquired Gamamabs Pharma SA’s AMHR2 Antibody Technology

      20.7 Sanofi Acquired Kymab Group Ltd.

      20.8 Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.

      20.9 Servier Acquired Symphogen A/S

      20.1 Gilead Sciences Acquired Forty Seven

      20.11 True North Acquired Stake In Biocon Biologics

      21 Pipeline Analysis

      22 Opportunities And Strategies

      22.1 Global Monoclonal Antibodies (mAbs) Market In 2028 – Countries Offering Most New Opportunities

      22.2 Global Monoclonal Antibodies (mAbs) Market In 2028 – Segments Offering Most New Opportunities

      22.3 Global Monoclonal Antibodies (mAbs) Market In 2028 – Growth Strategies

      22.3.1 Market Trend Based Strategies

      22.3.2 Competitor Strategies

      23 Monoclonal Antibodies Market, Conclusions And Recommendations

      23.1 Conclusions

      23.2 Recommendations

      23.2.1 Product

      23.2.2 Place

      23.2.3 Price

      23.2.4 Promotion

      23.2.5 People

      24 Appendix

      24.1 Geographies Covered

      24.2 Market Data Sources

      24.3 Research Methodology

      24.4 Currencies

      24.5 The Business Research Company

      24.6 Copyright and Disclaimer

    List Of Tables

      Table 1: Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million
    • Table 2: Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million
    • Table 3: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 4: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 5: Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 6: Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 7: Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 8: Asia-Pacific GDP Per Capita, By Country, 2018-2023, $
    • Table 9:  Asia-Pacific Population, By Country, 2018-2028, Millions
    • Table 10: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 11: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 12: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 13: China GDP Per Capita, 2018-2023, $
    • Table 14:  China Population, 2018-2028, Millions
    • Table 15: China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 16: China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 17: China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 18: India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 19: India Monoclonal antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 20: India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 21: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 22: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 23: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 24: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 25: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 26: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 27: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 28: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 29: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 30: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 31: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 32: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 33: Western Europe GDP Per Capita, By Country, 2018-2023, $
    • Table 34:  Western Europe Population, By Country, 2018-2028, Millions
    • Table 35: Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 36: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 37: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 38: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 39: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 40: UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 41: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 42: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 43: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 44: France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 45: France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 46: France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 47: Eastern Europe GDP Per Capita, By Country, 2018-2023, $
    • Table 48:  Eastern Europe Population, By Country, 2018-2028, Millions
    • Table 49: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 50: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 51: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 52: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 53: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 54: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 55: North America GDP Per Capita, By Country, 2018-2023, $
    • Table 56:  North America Population, By Country, 2018-2028, Millions
    • Table 57: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 58: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 59: North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 60: USA GDP Per Capita, 2018-2023, $
    • Table 61:  USA Population, 2018-2028, Millions
    • Table 62: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 63: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 64: USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 65: South America GDP Per Capita, By Country, 2018-2023, $
    • Table 66:  South America Population, By Country, 2018-2028, Millions
    • Table 67: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 68: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 69: South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 70: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 71: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 72: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 73: Middle East GDP Per Capita, By Country, 2018-2023, $
    • Table 74:  Middle East Population, By Country, 2018-2028, Millions
    • Table 75: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 76: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 77: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 78: Africa GDP Per Capita, By Country, 2018-2023, $
    • Table 79:  Africa Population, By Country, 2018-2028, Millions
    • Table 80: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 81: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 82: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Table 83: Global Monoclonal Antibodies (mAbs) Market, Key Competitor Estimated Market Shares, 2022, Percentage (%)
    • Table 84: Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion
    • Table 85: Merck & Co – Financial Overview, 2018 – 2022, $ Billion
    • Table 86: F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion
    • Table 87: Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion
    • Table 88: GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion
    • Table 89: Global Monoclonal Antibodies (MAbs) Market, Pipeline Analysis
    • Table 90: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), 2023 – 2028, By Country
    • Table 91: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Source, 2023 – 2028
    • Table 92: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Application, 2023 – 2028
    • Table 93: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By End-Users, 2023 – 2028
    • Table 94: Monoclonal Antibodies (mAbs) Market Data Sources

    List Of Figures

      Figure 1: Global Monoclonal Antibodies (mAbs) Market Segmentation By Source
    • Figure 2: Global Monoclonal Antibodies (mAbs) Market Segmentation By Application
    • Figure 3: Global Monoclonal Antibodies (mAbs) Market Segmentation By End-Users
    • Figure 4: Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million
    • Figure 5: Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million
    • Figure 6: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 7: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 8: Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 9: Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 10: Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 11: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 12: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 13: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 14: China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 15: China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 16: China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 17: India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 18: India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 19: India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 20: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 21: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 22: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 23: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 24: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 25: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 26: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 27: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 28: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 29: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 30: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 31: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 32: Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 33: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 34: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 35: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 36: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 37: UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 38: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 39: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 40: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 41: France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 42: France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 43: France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 44: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 45: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 46: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 47: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 48: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 49: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 50: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 51: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 52: North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 53: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 54: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 55: USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 56: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 57: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 58: South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 59: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 60: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 61: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 62: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 63: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 64: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 65: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 66: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 67: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
    • Figure 68: Global Monoclonal Antibodies (mAbs), Key Competitor Estimated Market Shares, 2022, Percentage (%)
    • Figure 69: Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion
    • Figure 70: Merck & Co – Financial Overview, 2018 – 2022, $ Billion
    • Figure 71: F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion
    • Figure 72: Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion
    • Figure 73: GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion
    • Figure 74: Geographic Regions Covered
    Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
    Read More
    Global Gene Therapy Market 2022 – Market Opportunities And Strategies
    Read More
    The Microbiome Market Share, Market Size, And Growth Rate 2022
    Read More
    Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
    Read More
    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Other Oncology Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other Distribution Channels), By Route Of Administration (Oral, Parental, Other Route Of Administration), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2032
    View Report
    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Corticosteroids Global Market Report 2024 – By Product (Glucocorticoids, Mineralocorticoids), By Application (Skin Allergies, Rheumatology Indications, Endocrinology, Acute Respiratory Diseases, Other Applications), By End User (Hospitals, Clinics, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
    View Report